Appili Therapeutics announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that the application has passed the examination. "We are pleased with this notice of allowance for a new patent that will further strengthen ATI-1501’s potential as a more convenient antibiotic treatment option," said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. "For far too long, the bitter taste of the current form of metronidazole has made it challenging for patients to take, increasing rates of treatment failure, infection recurrence and antibiotic resistance. This patent protects our investment in making metronidazole more accessible and easier to take for all patients, especially for the elderly and children who often have difficulty taking solid oral medicines."
Published first on TheFly
